CN103893225A - Application of ginkgo seed extract - Google Patents
Application of ginkgo seed extract Download PDFInfo
- Publication number
- CN103893225A CN103893225A CN201210586971.XA CN201210586971A CN103893225A CN 103893225 A CN103893225 A CN 103893225A CN 201210586971 A CN201210586971 A CN 201210586971A CN 103893225 A CN103893225 A CN 103893225A
- Authority
- CN
- China
- Prior art keywords
- semen ginkgo
- application
- ginkgo core
- pharmaceutical composition
- gout
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of a ginkgo seed extract in preparation of anti-gout medicaments, foods or healthcare products. The study finds that the ginkgo seed extract has a strong inhibiting effect on xanthine oxidase and tumor necrosis factor alpha. The ginkgo seed extract disclosed by the invention has a good anti-gout effect, and can be applied to preparation of the anti-gout medicaments, foods or healthcare products and pharmaceutical compositions. New use is developed for application of the ginkgo seed extract.
Description
Technical field
The invention belongs to the field of Chinese medicines, specifically, is the application for the preparation of medicine, food or the health product of gout about Semen Ginkgo core extract.
Background technology
Gout is due to purine metabolic disturbance in body, uric acid synthetic increase or discharge in vivo reduces, cause hyperuricemia, in the time that serum Uric Acid Concentration is too high, uric acid is just deposited on joint and subcutaneous tissue with the form of sodium salt and one group of different substantiality disease causing, often show as clinically that hyperuricemia, gouty acute arthritis are shown effect repeatedly, the tophaceous feature that is formed as, severe patient can cause joint deformity and dysfunction or gouty nephropathy.Xanthine oxidase is that one can catalysis hypoxanthine generates xanthine, and then generates uric acid, and directly catalysis xanthine generates the enzyme of uric acid again, research discovery, and the inhibitor taking xanthine oxidase as action target spot has good gout application prospect.
Conventional anti-gout drugs has colchicine, nonsteroidal antiinflammatory drug, uricosureic agent, xanthine oxidase inhibitor etc. clinically.Colchicine side effect is larger, the digestive tract reactions such as common nausea,vomiting,diarrhea, and severe patient can cause leukopenia, aplastic anemia, abnormal liver function etc.; Non-steroidal drug can cause the side effect of gastrointestinal tract, kidney, central nervous system, skin, liver etc.; Uricosureic agent, as probenecid can cause kidney damage and renal calculus etc., benzbromarone can cause gastrointestinal reaction, renal calculus, renal colic, bring out arthritis acute attack etc.; Xanthine oxidase inhibitor, if allopurinol is a kind of purine analogue, it is the medicine of the listing sixties in last century, although adopt so far always, but also there are a lot of side effect, can there is heating, allergic rash, stomachache, diarrhoea, leukocyte and thrombocytopenia in patient, the even side effect such as liver function injury.
Therefore, find safer anti-gout drugs, especially xanthine oxidase inhibitor, seems particularly important.
Tumor necrosis factor α (TNF α) is a kind of proinflammatory cytokine mainly being produced by mononuclear cell and macrophage, and participates in normal inflammatory reaction and immunoreation.Bibliographical information; TNF alpha expression inhibitor can be used for treating multiple inflammatory disease (the 1.Catrina AI such as gouty arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile chronic arthritis, ankylosing spondylitis; Trollmo C; af Klint E, et al.Arthritis Rheum.2005; 52:61 – 72; 2.Komatsu M, Kobayashi D, Saito K, et al.Clin Chem.2001; 47:1297 – 1301; 3.Van den Brande JM, Braat H, van den Brink GR, et al.Gastroenterology.2003; 124:1774 – 1785).
Semen Ginkgo core is the mature seed of Ginkgoaceae deciduous tree Semen Ginkgo (Ginkgo biloba L.), and gather autumn, and Semen Ginkgo contains a large amount of protein, starch, fatty oil, cyanogen glycoside, several amino acids etc.Semen Ginkgo can match with pig, sheep, beef and bird egg food, makes delicious food.
Summary of the invention
Present inventor finds in the research process of being engaged in xanthine oxidase inhibitor, and Semen Ginkgo core extract has the activity of good inhibition xanthine oxidase, can be used to treat gout and produce by xanthine the series of symptoms that uric acid causes.Semen Ginkgo core extract has the effect of good inhibition TNF α simultaneously, can alleviate the inflammatory symptom that gout is followed.In addition, Semen Ginkgo core is a kind of medicine-food two-purpose material, safe.
Therefore, the object of the present invention is to provide the application of Semen Ginkgo core extract for the preparation of anti-gout drugs, food or health product.
According to a preferred embodiment of the present invention, described medicine, food or health product are for suppressing the activity of xanthine oxidase.
According to a further advantageous embodiment of the invention, described medicine, food or health product are for suppressing the activity of tumor necrosis factor α.
According to the present invention, described Semen Ginkgo core extract is by obtaining Semen Ginkgo core with alcohol reflux.
According to one embodiment of present invention, described Semen Ginkgo core extract obtains by the following method:
By 6～12 times of amount 40%～95% organic solvents for Semen Ginkgo core, heating and refluxing extraction 1～3 time, 1～3h/ time, filter merging filtrate, filtrate decompression is concentrated, and concentrated solution is dried to obtain extract powder.
Preferably, described extraction solvent is lower alcohol, and described lower alcohol is selected from: methanol, ethanol, propanol, isopropyl alcohol etc.
In addition, the present invention also provides a kind of pharmaceutical composition of gout, comprises described Semen Ginkgo core extract and at least one pharmaceutically suitable carrier for the treatment of effective dose.
Wherein, described pharmaceutically suitable carrier includes but not limited to: soft phospholipid, aluminium stearate, aluminium oxide, ion exchange material, self-emulsifying drug delivery system, tween or other surfactants, serum albumin, buffer substance are if phosphate, glycine, sorbic acid, water, salt, electrolyte are as sulfate protamine, sodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salt, magnesium silicate, satisfied fatty acid partial glycerol ester admixture etc.
Pharmaceutical composition of the present invention also can comprise the excipient substance that one or more are conventional, as binding agent (as microcrystalline Cellulose), filler (as starch, glucose, Lactis Anhydrous and lactose beadlet), disintegrating agent (as cross-linked pvp, crosslinked carboxymethyl fecula sodium, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose), lubricant (as magnesium stearate) and absorption enhancer, absorption carrier, flavouring agent, sweeting agent, excipient, diluent, wetting agent etc.
Described pharmaceutical composition can be prepared into oral formulations, non-intestinal drug delivery agent and local administration preparation by this area conventional method; Wherein, oral formulations comprises tablet, granule, suspension, capsule, solution etc., and non-intestinal drug delivery agent comprises injection; Local administration preparation comprises cream, patch, ointment, spray, gel etc.
Beneficial effect of the present invention: Semen Ginkgo core extract of the present invention has stronger inhibitory action to xanthine oxidase and tumor necrosis factor α, illustrate that Semen Ginkgo core extract of the present invention has good gout effect, can be used for preparing anti-gout drugs or pharmaceutical composition, for the application and development of Semen Ginkgo core extract a kind of new purposes.
Detailed description of the invention
Below in conjunction with specific embodiment, the invention will be further described.Should be understood that following examples are only for the present invention is described but not for limiting scope of the present invention.
Related percentage ratio (%) in following examples, except special instruction, is mass percent.
In context of the present invention, " treatment effective dose " refers to the amount of the extract that can reach therapeutic effect.Those skilled in the art can understand " treatment effective dose " and can and may share etc. with other treatment agent and different along with the use of the mode of administration, carrier.
" pharmaceutically suitable carrier " can not destroy the pharmaceutical active of Semen Ginkgo core extract of the present invention, simultaneously its effective dose, and can bringing into play pharmaceutical carrier, to make the consumption of used time nontoxic to human body.
embodiment 1, Semen Ginkgo core extract preparation
Medicinal material coarse powder is appropriate, 10 times of amount 70% ethanol, and heating and refluxing extraction 3 times, 2h/ time, filter merging filtrate, filtrate decompression is concentrated, and concentrated solution is dried to obtain extract powder.
embodiment 2, the inhibitory action of Semen Ginkgo core extract to xanthine oxidase
Experiment material:
Tested medicine: Semen Ginkgo core extract (sample prepared by embodiment 1), be dissolved in DMSO, be prepared into 60mg/mL mother solution.
Xanthine oxidase: Sigma, Cat.:X1875
Xanthine: Sigma, Cat.:X7375
Positive control medicine: allopurinol (Jiangsu side forces medicine)
Experimental technique:
Using potassium phosphate buffer as diluent, prepare medicinal liquid, xanthine oxidase (0.04U/mL) and the xanthine solution (0.8mM) of different operating concentration, in 96 hole analysis plates, add 50 μ L medicinal liquids, 50 μ L xanthine oxidases and 100 μ L xanthine solution, 290nm place is detected by microplate reader, the numerical value that records absorbance and absorbance growth every 5 seconds, records 10 minutes altogether.
Experimental result is as shown in the following Table 1:
Table 1, the inhibitory action of Semen Ginkgo core extract to xanthine oxidase
The experimental result of above table 1 shows, Semen Ginkgo core extract has the effect of good inhibition xanthine oxidase, and this inhibitory action is dose-dependence.
Embodiment 3, the inhibitory action of Semen Ginkgo core extract to tumor necrosis factor α
Experiment material:
Tested medicine: Semen Ginkgo core extract (sample prepared by embodiment 1), be dissolved in DMSO, be prepared into 60mg/mL mother solution.
TNF α ELISA test kit: R & D, Cat.:DY210
Positive control medicine: IKK-2inhibitor IV(Santa cruz, Cat.:sc-203083)
Lipopolysaccharide (LPS): Sigma, Cat.:L6529
Experimental technique:
Get fresh normal adults whole blood, adopt density－gradient centrifuga－tion method to separate and obtain human peripheral blood single nucleus cell (PBMC), after counting, be inoculated in 96 porocyte culture plates, add the medicine of variable concentrations, after pretreatment 30 minutes, lipopolysaccharide (LPS) stimulation is spent the night, and second day, carries out ELISA experiment detect TNF α protein content by TNF α ELISA kit method.
Experimental result is as shown in the following Table 2:
Table 2, the inhibitory action of Semen Ginkgo core extract to tumor necrosis factor α (TNF α)
The experimental result of above table 2 shows, Semen Ginkgo core extract has the effect of good inhibition tumor necrosis factor α, and this inhibitory action is dose-dependence.
In sum, Semen Ginkgo core extract has good inhibitory action to xanthine oxidase and tumor necrosis factor α, can be used for medicine, food or the health product of preparation treatment gout, or further make the pharmaceutical composition for the treatment of gout, except the Semen Ginkgo core extract taking treatment effective dose is as active component, described pharmaceutical composition also comprises one or more pharmaceutically suitable carrier, and described pharmaceutically suitable carrier can be selected conventional carrier as known in the art; In addition, described pharmaceutical composition can also comprise the excipient substance that one or more are conventional, and this is apparent for a person skilled in the art.Preferably, the Semen Ginkgo core extract of the present invention as active component that pharmaceutical composition of the present invention contains 0.1-99.9% percentage by weight.The route of administration of described Semen Ginkgo core extract and pharmaceutical composition can be oral, Sublingual, percutaneous, through muscle or subcutaneous, mucocutaneous, vein, urethra, vagina etc.The consumption of described Semen Ginkgo core extract and pharmaceutical composition can be according to the difference of route of administration, patient's age and body weight, disease serious degree and difference, and its daily dose can be 0.001～100mg/kg, can be in single or divided doses.The present invention further proposes Semen Ginkgo core extract or the purposes in prevention and treatment gout relevant disease taking its compositions as primary activity composition.Before not departing from spirit of the present invention, put, those skilled in the art can be equal to and change and modify it, and described change and modification fall into the coverage of the application's claims equally.
Claims (10)
1. the application of Semen Ginkgo core extract, is characterized in that, for the preparation of medicine, food or the health product of gout.
2. application as claimed in claim 1, is characterized in that, described medicine, food or health product are for suppressing the activity of xanthine oxidase.
3. application as claimed in claim 1, is characterized in that, described medicine, food or health product are for suppressing the activity of tumor necrosis factor α.
4. the application as described in any one in claim 1～3, is characterized in that, described Semen Ginkgo core extract is by obtaining Semen Ginkgo core with alcohol reflux.
5. application as claimed in claim 4, is characterized in that, described Semen Ginkgo core extract obtains by the following method:
By 6～12 times of amount 40%～95% organic solvents for Semen Ginkgo core, heating and refluxing extraction 1～3 time, 1～3h/ time, filter merging filtrate, filtrate decompression is concentrated, and concentrated solution is dried to obtain extract powder.
6. application as claimed in claim 5, is characterized in that, described organic solvent is selected from: methanol, ethanol, propanol and isopropyl alcohol.
7. a pharmaceutical composition for gout, is characterized in that, comprises in the claim 1～6 for the treatment of effective dose Semen Ginkgo core extract and at least one pharmaceutically suitable carrier described in any one.
8. pharmaceutical composition as claimed in claim 7, it is characterized in that, described pharmaceutically suitable carrier is selected from: soft phospholipid, aluminium stearate, aluminium oxide, ion exchange material, self-emulsifying drug delivery system, tween or other surfactants, serum albumin, buffer substance are if phosphate, glycine, sorbic acid, water, salt, electrolyte are as sulfate protamine, sodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salt, magnesium silicate, satisfied fatty acid partial glycerol ester admixture.
9. pharmaceutical composition as claimed in claim 7, is characterized in that, also comprises the excipient substance that one or more are conventional.
10. pharmaceutical composition as claimed in claim 7, is characterized in that, the dosage form of described pharmaceutical composition comprises oral formulations, non-intestinal drug delivery agent and local administration preparation; Wherein, oral formulations comprises tablet, granule, suspension, capsule and solution, and non-intestinal drug delivery agent comprises injection; Local administration preparation comprises cream, patch, ointment, spray and gel.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210586971.XA CN103893225A (en) | 2012-12-28 | 2012-12-28 | Application of ginkgo seed extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210586971.XA CN103893225A (en) | 2012-12-28 | 2012-12-28 | Application of ginkgo seed extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103893225A true CN103893225A (en) | 2014-07-02 |
Family
ID=50985012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210586971.XA Pending CN103893225A (en) | 2012-12-28 | 2012-12-28 | Application of ginkgo seed extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103893225A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111265557A (en) * | 2020-03-19 | 2020-06-12 | 广西馨海药业科技有限公司 | Semen ginkgo extract for relieving cough and asthma, composition, extraction method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049301A (en) * | 2007-05-14 | 2007-10-10 | 湖北中医学院 | Pharmaceutical preparation of biflavone compound for anti gout |
| CN102641278A (en) * | 2012-04-06 | 2012-08-22 | 王青 | Application of ginkgolic acid in treating arthritis |
-
2012
- 2012-12-28 CN CN201210586971.XA patent/CN103893225A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049301A (en) * | 2007-05-14 | 2007-10-10 | 湖北中医学院 | Pharmaceutical preparation of biflavone compound for anti gout |
| CN102641278A (en) * | 2012-04-06 | 2012-08-22 | 王青 | Application of ginkgolic acid in treating arthritis |
Non-Patent Citations (1)
| Title |
|---|
| 赵春芳等: "白果活性成分的提取及其功效研究进展", 《仲恺农业工程学院学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111265557A (en) * | 2020-03-19 | 2020-06-12 | 广西馨海药业科技有限公司 | Semen ginkgo extract for relieving cough and asthma, composition, extraction method and application thereof |
| CN111265557B (en) * | 2020-03-19 | 2021-12-07 | 广西馨海药业科技有限公司 | Semen ginkgo extract for relieving cough and asthma, composition, extraction method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10575537B2 (en) | Saury Maillard peptide and its preparation method and application | |
| EP2517711B1 (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages | |
| CN105395577A (en) | Composition capable of decreasing uric acid and preparation thereof | |
| CN103893226A (en) | Application of nutmeg extract | |
| CN110478373B (en) | Application of antarctic krill oil in preparation of medicine for resisting hyperuricemia or gout | |
| CN104069391B (en) | A kind of Chinese medicine composition for treating gout and hyperuricemia and preparation method thereof | |
| CN116196323B (en) | Application of typha saponin in preparing medicament for reducing uric acid and/or treating kidney injury | |
| CN103893225A (en) | Application of ginkgo seed extract | |
| CN101904856A (en) | Application of 1,6-diphosphofructose and derivative thereof in preparing animal medical health care products | |
| CN114848699B (en) | Composition with uric acid reducing effect and preparation method and application thereof | |
| CN101396437B (en) | Anti-gout drop pills of pure traditional Chinese medicine | |
| CN108379455B (en) | Uric acid reducing composition | |
| TW201247212A (en) | Use of ginseng flower extract to prevent or cure diseases or symptoms caused by abnormally high blood uric acid concentration | |
| CN108785300B (en) | Application of alpha-mangostin in preparation of medicine for preventing and treating gout and hyperuricemia | |
| CN101152262B (en) | Anti-gout novel medical preparation | |
| CN111297842A (en) | Use of omega fatty acids for modulating uric acid levels in vivo | |
| CN111419885A (en) | Inonotus obliquus extract with uric acid reducing effect | |
| CN105982921A (en) | Composition for treating gout and application thereof | |
| CN105030952B (en) | A kind of composition is preparing the application in preventing urinary calculus drug | |
| CN111053859A (en) | Traditional Chinese medicine composition for reducing uric acid and preparation method and application thereof | |
| CN108720013A (en) | The formula and processing technology of the health food of one group of Soboring-up liver-protecting being made of fructose and tea extract | |
| JP7137368B2 (en) | Composition for promoting sodium excretion and/or suppressing sodium absorption | |
| CN102949434B (en) | Purpose of bitter marrow squash extracts in anti-gout medicine preparation | |
| CN115350224B (en) | Uric acid reducing composition and preparation method thereof | |
| CN106138194A (en) | A kind of compound Chinese medicinal preparation treating hyperuricemia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140702 |